Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

On July 26, 2024, the highly anticipated 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Complex Infectious Diseases (OFCID) and the Annual Meeting of the Global Chinese Society of Clinical Microbiology and Infectious Diseases, was grandly inaugurated at the Shanghai International Conference Center. Themed "Precision Diagnosis, Precision Control," this year's conference aims to enhance the scientific and precise approach to infection prevention and control in China. Marking SIFIC's 20th anniversary, the conference not only reflected on past achievements but also looked forward to the boundless possibilities in the field of infection control, inspiring every participant to move forward together in writing a new chapter for infection prevention and control.
Emerging Perspectives: July Literature Digest (Part 2)

Emerging Perspectives: July Literature Digest (Part 2)

In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!
ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

For many years, platinum-based chemotherapy has been the standard treatment for metastatic urothelial carcinoma. However, this year’s EV-302/KEYNOTE-A39 study results, published in the New England Journal of Medicine (NEJM), demonstrated that the combination of enfortumab vedotin and pembrolizumab (EV+P) significantly improves survival outcomes for patients with locally advanced or metastatic urothelial carcinoma. The 2024 ASCO Breakthrough conference, held from August 8-10 in Yokohama, Japan, presented the efficacy and patient-reported outcomes (PROs) from the KEYNOTE-A39 study. Here is a summary for our readers.
ASCOBT24 | Evolving Treatment Prospects for mHSPC and Optimizing Cabazitaxel Benefit in mCRPC Patients

ASCOBT24 | Evolving Treatment Prospects for mHSPC and Optimizing Cabazitaxel Benefit in mCRPC Patients

The ASCO Breakthrough Summit, co-hosted by the American Society of Clinical Oncology (ASCO), the Japanese Society of Clinical Oncology (JSCO), and the Japanese Society of Medical Oncology (JSMO), in collaboration with several authoritative societies in the Asia-Pacific region, including the Chinese Anti-Cancer Association (CACA) and the Chinese Society of Clinical Oncology (CSCO), was held from August 8-10 in Yokohama, Japan. This year’s conference featured two significant advances in prostate cancer research (Abstract Nos. 118 and 119), which are summarized below.
2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

In the spirit of "Healthy China, Urology First," the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was grandly held in Xi'an, Shaanxi Province, from August 8th to 11th, 2024. The event showcased the latest achievements in urological medicine from a global and multidimensional perspective. In recent years, with the deepening of molecular exploration, prostate cancer treatment has entered the era of precision medicine. Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University, to discuss the significance, recent breakthroughs, and future applications of precision medicine in prostate cancer.
2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

Prostate cancer is one of the most common malignant tumors in the male urinary system, with over 110,000 new cases diagnosed annually in China. The bones are the primary site of metastasis for prostate cancer, leading to bone-related events (BREs) such as pathological fractures, spinal cord compression, and bone pain, which significantly impact patients' quality of life and long-term prognosis. Studies have shown that 60%-75% of prostate cancer patients with bone metastases experience severe bone pain at diagnosis, causing substantial disruption to their daily lives. Bone-related events, represented by bone pain, accompany the entire course of disease progression in prostate cancer bone metastasis patients, imposing a heavy economic burden on patients, families, and society. Urology Frontier has invited Dr. Shun Zhang from Medical School of Nanjing University Affiliated Nanjing Drum Tower Hospital to share insights on this topic.
AIDS Five Minutes | Dr. Wei Cao: Treatment and Management Practices in the Post-HAART Era of HIV

AIDS Five Minutes | Dr. Wei Cao: Treatment and Management Practices in the Post-HAART Era of HIV

"The continuous advancements and remarkable success of Highly Active Antiretroviral Therapy (HAART) have made long-term survival for HIV patients a reality. However, the persistent presence of the HIV virus, chronic inflammation associated with the virus, and the lifelong impact of medication have led to chronic complications, such as metabolic diseases, becoming significant factors affecting the clinical outcomes of patients undergoing long-term treatment. These issues have become crucial in the treatment and management of patients. One of the key focuses of the 25th International AIDS Conference (AIDS2024) was the ongoing attention to non-AIDS-related complications, which brought new insights into their treatment and management."
AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

From July 22-26, 2024, the 25th International AIDS Conference（AIDS 2024） was held in Munich, Germany, bringing together 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in HIV prevention and treatment. At the conference, Dr. Biao Zhu from the First Affiliated Hospital,Zhejiang University School of Medicine presented a retrospective study conducted by his team. The report analyzed the changing disease spectrum of hospitalized HIV-infected patients in comprehensive hospitals in Eastern China over the past 12 years, revealing not only the survival status of HIV-infected patients in the Yangtze River Delta region but also significant changes in their disease spectrum as they achieve long-term survival.
Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

To further enhance the diagnostic and treatment techniques for leukemia and lymphoma in China, the 8th Hematology Oncology Academic Conference was held from July 26 to 28 in Harbin. This event was jointly organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the Lymphoma Expert Committee, and co-hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. The conference aimed to provide a significant platform for in-depth learning and extensive exchange among experts and scholars in the field of hematologic oncology. On this occasion, Hematology Frontier had the privilege of inviting Dr. Qian Jiang from Peking University People's Hospital to share her insights on the treatment models and unmet needs for newly diagnosed chronic myeloid leukemia (CML) patients.
Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Over time, alcohol consumption has become a significant public health concern. Alcohol is associated with more than 200 diseases, including diabetes and cirrhosis, contributing to 5.3% of global mortality. Despite increased awareness of alcohol's harmful effects, overall consumption levels have not decreased. Previous studies have investigated the impact of diabetes on patients with alcoholic cirrhosis, but the relationship between diabetes and clinical outcomes in these patients has remained unclear. Recently, a study published in Hepatology International has shed light on the relationship between diabetes and clinical outcomes in patients with alcohol-related cirrhosis.